Occupational exposure to respirable crystalline silica and autoimmunity: sex differences in mouse models

International audienc

Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis

International audienceOver the past few years, genetics has significantly improved the understanding of interstitial lung diseases (ILD)..

The collaboration of clinical pharmacists and physicians for medication safety

International audienc

M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis

International audienc

ILD and Mediastinal Lymph Nodes A CT-Based Biomarker Beyond Nosological and Etiological Borders?

International audienc

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations

International audienceApixaban and rivaroxaban have first-line use for many patients needing anticoagulation for venous thromboembolism (VTE). The pharmacokinetics of these drugs in non-obese subjects have been extensively studied, and, while changes in pharmacokinetics have been documented in obese patients, data remain scarce for these anticoagulants. The aim of this study was to perform an external validation of published population pharmacokinetic (PPK) models of apixaban and rivaroxaban in a cohort of obese patients with VTE. A literature search was conducted in the PubMed/MEDLINE, Scopus, and Embase databases following the PRISMA statement. External validation was performed using MonolixSuite software, using prediction-based and simulation-based diagnostics. An external validation dataset from the university hospitals of Brest and Rennes, France, included 116 apixaban pharmacokinetic samples from 69 patients and 121 rivaroxaban samples from 81 patients. Five PPK models of apixaban and 16 models of rivaroxaban were included, according to the inclusion criteria of the study. Two of the apixaban PPK models presented acceptable performances, whereas no rivaroxaban PPK model did. This study identified two published models of apixaban applicable to apixaban in obese patients with VTE. However, none of the rivaroxaban models evaluated were applicable. Dedicated studies appear necessary to elucidate rivaroxaban pharmacokinetics in this population

Elucidating in utero fetal demise time to reassemble the pieces of the puzzle?

International audienc

Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study

International audienc